Adding lanreotide to everolimus significantly prolonged progression-free survival compared with everolimus alone in patients ...

A novel blood-based test for early detection of colorectal cancer in average-risk adults met the primary endpoints of ...

The Phase III trial saw a clinically meaningful benefit in overall survival with a combination of Itovebi alongside Ibrance ...

First-line treatment with targeted therapies plus chemotherapy offered overall response benefits in BRAF V600E-mutant ...

If the drug is approved by the US Food and Drug Administration for the treatment of acute pain in January as expected, the ...

Genentech, a member of Roche (RHHBY), announced topline results from the overall survival analysis of the Phase III INAVO120 study ...

The effective use of ADA in bioprocessing, though, requires a multidisciplinary team, from a program lead and subject-matter ...

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Wafaa Mamilli (1967) will join the company as Chief Digital ...

The analysis of numerous clinical trials saw an uptick in Indigenous American and Asian participants in decentralised trials.

Shares of Lonza Group AG (SIX: LONN) fell more than 3% on Wednesday after the company reported full-year 2024 earnings that ...

During a Case-Based Roundtable® event, Thach-Giao Truong, MD, discussed how data from the CheckMate-067 and RELATIVITY-047 ...

Atalanta Therapeutics has bagged $97 million, money the biotech plans to use to launch clinical trials for its small ...